Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Common Equity (2016 - 2026)

Amphastar Pharmaceuticals has reported Common Equity over the past 13 years, most recently at $788.8 million for Q4 2025.

  • For Q4 2025, Common Equity rose 7.72% year-over-year to $788.8 million; the TTM value through Dec 2025 reached $788.8 million, up 7.72%, while the annual FY2025 figure was $788.8 million, 7.72% up from the prior year.
  • Common Equity for Q4 2025 was $788.8 million at Amphastar Pharmaceuticals, up from $776.7 million in the prior quarter.
  • Over five years, Common Equity peaked at $788.8 million in Q4 2025 and troughed at $430.2 million in Q3 2021.
  • A 5-year average of $604.9 million and a median of $592.2 million in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: dropped 4.61% in 2021 and later increased 22.56% in 2024.
  • Year by year, Common Equity stood at $445.5 million in 2021, then rose by 18.66% to $528.7 million in 2022, then increased by 20.95% to $639.4 million in 2023, then rose by 14.53% to $732.3 million in 2024, then increased by 7.72% to $788.8 million in 2025.
  • Business Quant data shows Common Equity for AMPH at $788.8 million in Q4 2025, $776.7 million in Q3 2025, and $757.5 million in Q2 2025.